NCT00565565View on ClinicalTrials.gov

Single Dose Escalation Study in Patients With Chronic Heart Failure

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions
Heart Failure
Interventions
DRUG

BAY60-4552

Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg

Trial Locations (2)

35392

Giessen

61231

Bad Nauheim

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00565565 - Single Dose Escalation Study in Patients With Chronic Heart Failure | Biotech Hunter | Biotech Hunter